These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1162 related articles for article (PubMed ID: 33160563)

  • 1. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Chauhan A; Agarwal A; Jaiswal N; Singh M
    Lancet; 2020 Nov; 396(10261):1485-1486. PubMed ID: 33160563
    [No Abstract]   [Full Text] [Related]  

  • 2. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Lodge A
    Lancet; 2020 Nov; 396(10261):1486. PubMed ID: 33160564
    [No Abstract]   [Full Text] [Related]  

  • 3. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
    Voysey M; Pollard AJ
    Lancet; 2020 Nov; 396(10261):1486-1487. PubMed ID: 33160565
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 disrupts vaccine delivery.
    Nelson R
    Lancet Infect Dis; 2020 May; 20(5):546. PubMed ID: 32311326
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 vaccines: early success and remaining challenges.
    Bar-Zeev N; Inglesby T
    Lancet; 2020 Sep; 396(10255):868-869. PubMed ID: 32896290
    [No Abstract]   [Full Text] [Related]  

  • 6. The Covid-19 Vaccine-Development Multiverse.
    Heaton PM
    N Engl J Med; 2020 Nov; 383(20):1986-1988. PubMed ID: 32663910
    [No Abstract]   [Full Text] [Related]  

  • 7. The Race to Develop a COVID-19 Vaccine.
    Am J Nurs; 2020 Oct; 120(10):14-15. PubMed ID: 32976132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audio Interview: New SARS-CoV-2 Vaccine Results, with Peter Piot.
    Rubin EJ; Baden LR; Piot P; Morrissey S
    N Engl J Med; 2020 Jul; 383(5):e57. PubMed ID: 32726549
    [No Abstract]   [Full Text] [Related]  

  • 9. Keeping track of the SARS-CoV-2 vaccine pipeline.
    Parker EPK; Shrotri M; Kampmann B
    Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and Concept for COVID-19 Vaccine Development.
    Wu SC
    Biotechnol J; 2020 Jun; 15(6):e2000147. PubMed ID: 32304139
    [No Abstract]   [Full Text] [Related]  

  • 11. A vaccine is not too far for COVID-19.
    Patel SK; Pathak M; Tiwari R; Yatoo MI; Malik YS; Sah R; Rabaan AA; Sharun K; Dhama K; Bonilla-Aldana DK; Rodriguez-Morales AJ
    J Infect Dev Ctries; 2020 May; 14(5):450-453. PubMed ID: 32525830
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials: Too Risky, Too Soon.
    Dawson L; Earl J; Livezey J
    J Infect Dis; 2020 Jul; 222(3):514-516. PubMed ID: 32496536
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2.
    Plotkin SA
    J Pediatric Infect Dis Soc; 2020 Nov; 9(5):517-518. PubMed ID: 32744616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronavirus Disease 2019: Is Everything Lawful to Create an Effective Vaccine?
    Cioffi A
    J Infect Dis; 2020 Jun; 222(1):169. PubMed ID: 32348489
    [No Abstract]   [Full Text] [Related]  

  • 15. Audio Interview: Covid-19 Vaccine Development.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Jul; 383(3):e40. PubMed ID: 32668131
    [No Abstract]   [Full Text] [Related]  

  • 16. Next-generation vaccine platforms for COVID-19.
    van Riel D; de Wit E
    Nat Mater; 2020 Aug; 19(8):810-812. PubMed ID: 32704139
    [No Abstract]   [Full Text] [Related]  

  • 17. Riding the coronacoaster of uncertainty.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2020 Jun; 20(6):629. PubMed ID: 32422202
    [No Abstract]   [Full Text] [Related]  

  • 18. Russian SARS-CoV-2 vaccine.
    Caddy S
    BMJ; 2020 Aug; 370():m3270. PubMed ID: 32839191
    [No Abstract]   [Full Text] [Related]  

  • 19. An Inactivated Virus Candidate Vaccine to Prevent COVID-19.
    Mulligan MJ
    JAMA; 2020 Sep; 324(10):943-945. PubMed ID: 32789500
    [No Abstract]   [Full Text] [Related]  

  • 20. Encouraging results from phase 1/2 COVID-19 vaccine trials.
    Bar-Zeev N; Moss WJ
    Lancet; 2020 Aug; 396(10249):448-449. PubMed ID: 32702300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 59.